Angle PLC - Surrey, England-based medical diagnostics - Signs contract with Eisai Inc, part of Tokyo-based pharmaceutical firm Eisai Co Ltd. Under the agreement, the two will engage in a pilot study worth USD250,000 to Angle. Angle will provide circulating-tumour-cells analysis using its Portrait HER2 assay to assess the response of breast cancer patients to Eisai's BB-1701 antibody-drug conjugate. BB-1701 targets HER2, a protein that speeds up the growth of breast cancer cells. Success in the phase two pilot study will offer the possibility for multiple follow-up studies.
"Angle's Portrait HER2 assay provides a way to evaluate HER2 status in patients where a tissue biopsy at the metastatic site either fails or is not feasible," Chief Executive Officer Andrew Newland says. "We are delighted that Eisai is utilising our new HER2 assay for this study and believe that a successful pilot study will lead the way to major expansion of this line of our business going forward."
Current stock price: 11.51 pence each, down 2.0% in London on Tuesday
12-month change: down 76%
By Hugh Cameron, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Angle (AGL)